High-Dose Quadrivalent Influenza Vaccine — Competitive Intelligence Brief

High-Dose Quadrivalent Influenza Vaccine (High-Dose Quadrivalent Influenza Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated influenza vaccine Immunology / Infectious Disease Small molecule

Target snapshot

High-Dose Quadrivalent Influenza Vaccine (High-Dose Quadrivalent Influenza Vaccine) — Tor Biering-Sørensen. A high-dose inactivated influenza vaccine that stimulates a stronger immune response by delivering four times the standard antigen dose to enhance antibody production and cellular immunity against four influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
High-Dose Quadrivalent Influenza Vaccine TARGET	High-Dose Quadrivalent Influenza Vaccine	Tor Biering-Sørensen	marketed	Inactivated influenza vaccine
Seasonal trivalent vaccine	Seasonal trivalent vaccine	Sinovac Biotech Co., Ltd	marketed	Inactivated influenza vaccine
trivalent seasonal influenza vaccine	trivalent seasonal influenza vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
Standard IIV4	Standard IIV4	Marshfield Clinic Research Foundation	marketed	Inactivated influenza vaccine
High Dose Trivalent Influenza Vaccine	High Dose Trivalent Influenza Vaccine	Brigham and Women's Hospital	marketed	Inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class